Avalo Therapeutics, Inc.
About Avalo Therapeutics, Inc.
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $59.0K
- Net income
- -$78.3M
- Total assets
- $116.5M
- Market cap
- $688.6M
- Operating margin
- -123601.7%
- Net margin
- -132642.4%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $59.0K
- Operating expenses
- $73.0M
- Operating income
- -$72.9M
- Income tax
- $165.0K
- Net income
- -$78.3M
- EPS (basic)
- $-5.84
- EPS (diluted)
- $-5.84
Balance sheet
- Total assets
- $116.5M
- Current assets
- $105.3M
- Total liabilities
- $33.4M
- Current liabilities
- $12.9M
- Shareholders’ equity
- $83.0M
Cash flow
- Operating cash flow
- -$51.5M
- Investing cash flow
- -$81.7M
- Financing cash flow
- $14.6M
- Net cash flow
- -$118.6M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $688.6M
- EPS (diluted)
- $-5.84
- Shares outstanding
- 52.6M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Nov 13, 2015
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $78.3M in FY2025.
- Revenue declined 99% from FY2021 to FY2025.
- Trading 43% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Avalo Therapeutics, Inc..
Write a review
News about Avalo Therapeutics, Inc.
News & sentiment via Polygon.io
